Literature DB >> 15093692

Expression of somatostatin receptors 1 and 2 in the adult mouse kidney.

Carlton M Bates1, Heather Kegg, Sandy Grady.   

Abstract

Systemic infusion of somatostatin in humans and rodents alters renal glomerular filtration rate, solute transport, and water clearance. Among the five different G-protein-coupled somatostatin receptors (SSTRs), SSTR1 is expressed in human kidney collecting ducts and SSTR2 is expressed in rat and human collecting ducts and glomeruli. Our laboratory recently localized SSTRs 3, 4, and 5 to mouse kidney proximal tubules. Our aim was to characterize the expression of somatostatin receptors 1 and 2 in mouse kidneys. We detected mRNA for somatostatin receptors 1 and 2 in the mouse kidney by reverse transcriptase-polymerase chain reaction (RT-PCR), with confirmation by Southern blotting. In contrast to the data in human kidneys, we localized SSTR1 proteins to mouse proximal tubules and glomerular podocytes. Similar to the reports in human and rat kidneys, we detected SSTR2 proteins in the murine glomerulus and collecting duct; we were further able to identify the specific SSTR2-positive cells as podocytes and principal cells, respectively. Thus, taken with our previously published results, the kidney expresses all five somatostatin receptors. Furthermore, the expression of the SSTRs in the mouse kidney correlates well with the known actions of somatostatin in the kidney.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093692     DOI: 10.1016/j.regpep.2003.12.015

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

1.  Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Authors:  R Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

2.  Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides.

Authors:  Zhengxin Cai; Barbara T Y Li; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Dalton Trans       Date:  2015-03-07       Impact factor: 4.390

Review 3.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

4.  Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Authors:  Esther Meijer; Folkert W Visser; Rene M M van Aerts; Charles J Blijdorp; Niek F Casteleijn; Hedwig M A D'Agnolo; Shosha E I Dekker; Joost P H Drenth; Johan W de Fijter; Maatje D A van Gastel; Tom J Gevers; Marten A Lantinga; Monique Losekoot; A Lianne Messchendorp; Myrte K Neijenhuis; Michelle J Pena; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Jack F Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  JAMA       Date:  2018-11-20       Impact factor: 56.272

5.  Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Authors:  Sunil Bhandari; Neil Watson; Ervine Long; Steve Sharpe; Wenwen Zhong; Shang-Zhong Xu; Stephen L Atkin
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

6.  Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate.

Authors:  Johanna Dalmo; Emelie Westberg; Lars Barregard; Lisa Svedbom; Martin Johansson; Margareta Törnqvist; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2014-10-31       Impact factor: 3.138

7.  A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice.

Authors:  Nouran R R Zaid; Peter Kletting; Gordon Winter; Vikas Prasad; Ambros J Beer; Gerhard Glatting
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.